Have a feature idea you'd love to see implemented?
Let us know!
XENE Xenon Pharmaceuticals Inc
Price (delayed)
$39.8
Market cap
$3.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.82
Enterprise value
$2.96B
Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of
Highlights
XENE's debt is down by 11% year-on-year and by 2.5% since the previous quarter
The company's equity rose by 25% YoY but it fell by 5% QoQ
The quick ratio has contracted by 4.5% from the previous quarter but it has grown by 3.5% YoY
The net income has declined by 22% year-on-year and by 7% since the previous quarter
The EPS fell by 6% YoY and by 2.9% QoQ
Key stats
What are the main financial stats of XENE
Market
Valuations
Earnings
Shares outstanding
76.24M
Market cap
$3.03B
Enterprise value
$2.96B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.78
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$213.83M
EBITDA
-$211.06M
Free cash flow
-$164.84M
Per share
Balance sheet
Liquidity
EPS
-$2.82
Free cash flow per share
-$2.12
Book value per share
$10.53
Revenue per share
$0
TBVPS
$10.73
Total assets
$835.9M
Total liabilities
$38.09M
Debt
$9.79M
Equity
$797.81M
Working capital
$629.94M
Debt to equity
0.01
Current ratio
22.21
Quick ratio
22.06
Net debt/EBITDA
0.37
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.7%
Return on equity
-24.7%
Return on invested capital
-27.6%
Return on capital employed
-26.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
XENE stock price
How has the Xenon Pharmaceuticals stock price performed over time
Intraday
1.17%
1 week
-4.67%
1 month
-9.98%
1 year
32.53%
YTD
-13.59%
QTD
1.09%
Financial performance
How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$255.52M
Net income
-$213.39M
Gross margin
N/A
Net margin
N/A
The operating income is down by 25% year-on-year and by 8% since the previous quarter
The net income has declined by 22% year-on-year and by 7% since the previous quarter
Growth
What is Xenon Pharmaceuticals's growth rate over time
Valuation
What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.78
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 6% YoY and by 2.9% QoQ
XENE's price to book (P/B) is 26% higher than its 5-year quarterly average of 3.0 and 8% higher than its last 4 quarters average of 3.5
The company's equity rose by 25% YoY but it fell by 5% QoQ
Efficiency
How efficient is Xenon Pharmaceuticals business performance
Xenon Pharmaceuticals's return on equity has increased by 5% YoY but it has decreased by 2.1% QoQ
Xenon Pharmaceuticals's return on assets has increased by 4% YoY but it has decreased by 2.2% QoQ
Dividends
What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for XENE.
Financial health
How did Xenon Pharmaceuticals financials performed over time
The total assets rose by 25% year-on-year but it has declined by 5% since the previous quarter
XENE's total liabilities is up by 10% year-on-year but it is down by 4.7% since the previous quarter
XENE's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% YoY
The company's equity rose by 25% YoY but it fell by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.